Eisai Co., Ltd. (TYO:4523)
5,076.00
+21.00 (0.42%)
Oct 23, 2026, 3:30 PM JST
Eisai Revenue
Eisai had revenue of 234.33B JPY in the quarter ending June 30, 2026, with 15.63% growth. This brings the company's total for the last twelve months to 857.06B, up 6.73% year-over-year. In the fiscal year ending March 31, 2026, Eisai had annual revenue of 825.38B with 4.56% growth. That makes Eisai the 2,434th largest company in the world by revenue and 240th in Japan.
Revenue (ttm)
857.06B
Revenue Growth
+6.73%
P/S Ratio
1.67
Revenue / Employee
81.29M
Employees
10,543
Market Cap
1.43T
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full Eisai breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 825.38B | 35.98B | 4.56% |
| Mar 31, 2025 | 789.40B | 47.65B | 6.42% |
| Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
| Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
| Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.62T |
| Shionogi & | 563.21B |
| Sumitomo Pharma | 474.79B |
| Towa Pharmaceutical | 279.94B |
| Sawai Group Holdings | 203.79B |
| Tsumura & Co. | 199.23B |
| Nippon Shinyaku | 180.29B |
| Mochida Pharmaceutical | 122.04B |
Eisai News
- 4 weeks ago - Merk; Eisai Win FDA Approval For WELIREG-LENVIMA In Advanced Kidney Cancer - Nasdaq
- 2 months ago - Eisai Earnings Call Transcript: Q1 2027 - Transcripts
- 2 months ago - Eisai Quarterly report: Q1 2027 - Filings
- 2 months ago - Eisai Slides: Q1 2027 - Filings
- 3 months ago - FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug - Reuters
- 4 months ago - UK, Japan agree tech partnership and vow fighter jet progress - Reuters
- 4 months ago - Eisai and CaringKind Launch New Initiative to Address Mealtime and Nutrition Needs for People Living with Alzheimer's Disease and Related Dementias - PRNewsWire
- 5 months ago - BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day - PRNewsWire